Table 3.

Discontinuation due to AEs in CIS studies

Study	Comparison	Follow-up (months)	Treatment arm events	Treatment group	Treatment events proportion (%)	Placebo arm events	Placebo group	Placebo events proportion (%)
PreCISe 2009	GA 20 mg daily vs. placebo	36	14	243	5.8	4	238	1.7
REFLEX 2012	IFN β-1a 44 μg SC thrice weekly vs. placebo	24	5	171	2.9	6	171	3.5
CHAMPS 2000	IFN β-1a 30 μg IM weekly vs. placebo	36	1	193	0.5	7	190	3.7
BENEFIT 2006	IFN β-1b 250 μg SC every other day vs. placebo	24	24	292	8.2	1	176	0.6